21st Century Therapeutics News


8/24/2015

Pharmaceutical Research Firm Receives an SBIR Grant from NIH

Detroit based 21st Century Therapeutics, Inc. (21CTI) received an SBIR research grant of $303 K from the National Center for Complementary & Integrative Health, National Institutes of Health (NIH), to develop a novel botanical drug to treat Methicillin-resistant Staphylococcus aureus (MRSA). This novel compound (KCR) from sycamore leaves was discovered and patented by Dr. Mark Hamann of Oxford based Oxford Pharmaceutical Development (OPD); KCR was subsequently licensed to 21CTI. According to 21CTI’s CEO, Dr. Frederick Valeriote, this is the sixth SBIR grant received by 21CTI and first SBIR for OPD.

More Information>>




7/16/2014

21st Century Therapeutics Scientific Article Downloaded/Viewed 280 Times

21-CTI's article, "Using a simple HPLC approach to identify the enzymatic products of UTL-5g, a small molecule TNF-@a inhibitor, from porcine esterase and from rabbit esterase," has been downloaded or viewed more than 280 times since its publication (as of July 16th, 2014).

More Information>>




6/10/2014

Pharmaceutical Research Firm Receives an SBIR Grant from NIH

Ferndale based 21st Century Therapeutics, Inc. (21CTI) received a two-year SBIR research grant of $674 K from National Institutes of Health (NIH) to develop a novel ELISA kit for screening potential Janus Kinase 3 (JAK3) Inhibitors. According to 21CTI’s CEO, Dr. Frederick Valeriote, this is the fifth SBIR grant received by 21CTI.

Full Article>>




5/21/2014

Dr. Shaw Interviewed by International Innovation

Reducing the side-effects of chemotherapy - Medicinal chemist and cancer researcher Dr. JiaJiu Shaw discusses the need to develop novel chemoprotective agents, and shares the details of his own work towards accomplishing this goal.

Full Article>>




04/23/2014

Pharmaceutical Research Firm Signs Agreement with Chinese Firm for Enzyme Immobilization

Ferndale, Michigan based 21st Century Therapeutics, Inc. (21CTI) signed an agreement with a Chinese technology company, Beijing WecareS Biopharmaceutical Co. Ltd., to provide enzyme immobilization services in the United States. “This collaboration will help us expand our technology into enzyme business, broaden our areas of expertise, and help generate some short-term revenues”, said Dr. Frederick Valeriote, CEO of 21CTI.

Full Article>>




05/01/2013

Pharmaceutical Research Firm Receives a Phase I SBIR Grant from NIH

Ferndale based 21st Century Therapeutics, Inc. (21CTI) received a one-year research grant of $276 K from National Institutes of Health (NIH) to study a small-molecule Tumor Necrosis Factor-a (TNF-a) to treat oxaplatin-induced thrombocytopenia. According to 21CTI’s CEO, Dr. Frederick Valeriote, this is the fourth SBIR grant received by 21CTI.

Full Article>>




07/16/2012

Pharmaceutical Research Firm Signs Agreement with a Mississippi Biotech Company for anti-MRSA Antibiotic Drug Development

Ferndale, Michigan based 21st Century Therapeutics, Inc. (21CTI) signed an agreement with the Oxford, Mississippi-based biotech company, Oxford Pharmaceuticals (Oxford), to develop a novel anti-MRSA (methicillin-resistant staphylococcus aureus) antibiotic to combat this devastating hospital-based bacterial infection. 21CTI’s CEO, Dr. Frederick Valeriote indicated that “MRSA strains are often resistant to many other common antibiotics such as streptomycin, erythromycin and ciprofloxacin making it especially dangerous as this multiple drug resistance greatly limits potentially effective antibiotics. Indeed, some MRSA strains have become resistant to vancomycin making therapeutic options minimal.”

Full Article>>




05/20/2012

Pharmaceutical Research Firm Signs Agreement with a Chinese Firm for Drug Development

Ferndale, Michigan based 21st Century Therapeutics, Inc. (21CTI) signed an agreement with the Chinese pharmaceutical company, Chendu Xin Fanyu Biomedical (XFY), to develop a small-molecule Tumor Necrosis Factor-α (TNF-α) inhibitor as a chemoprotector to reduce side effects induced by platinum anticancer drugs. According to 21CTI’s CEO, Dr. Frederick Valeriote, this is the first intercontinental agreement signed by 21CTI. “This collaboration will help us speed up the preclinical development of UTL-5g as a novel chemoprotector”, said Valeriote.

Full Article>>




09/23/2011

Pharmaceutical Research Firm Receives a $186 K Contract from NCI

Ferndale based 21st Century Therapeutics, Inc. (21CTI) received a Phase I SBIR Contract of $186K from the National Cancer Institute (NCI) as a 100% funding source to develop a small-molecule Tumor Necrosis Factor-α (TNF-α) inhibitor as a radioprotector to reduce radiotherapy-induced side effects. According to 21CTI’s CEO, Dr. Frederick Valeriote, this is the first SBIR Contract received by 21CTI.

Full Article>>




08/31/2011

Pharmaceutical Research Firm Receives a $1.1 million Grant from NIH

Ferndale based 21st Century Therapeutics, Inc. (21CTI) received a two-year research grant of $1.1 million from National Institutes of Health (NIH) to study a small-molecule Tumor Necrosis Factor-α (TNF-α) inhibitor as a chemoprotector to reduce cisplatin-induced side effects. According to 21CTI’s CEO, Dr. Frederick Valeriote, this is the third SBIR grant received by 21CTI.

Full Article>>